Generated by AI
Geron Corporation is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for blood cancers and related hematologic disorders. Its lead product is RYTELO (imetelstat), a telomerase inhibitor used in the treatment of adult patients with lower-risk myelodysplastic syndromes who have transfusion-dependent anemia. The company’s work centers on oncology programs that target abnormal blood-forming cells, with an emphasis on myeloid malignancies and other disorders of the bone marrow and blood. Geron Corporation serves the specialized hematology-oncology market by advancing targeted treatment options for patients with limited alternatives, supporting use across clinical practice, specialty care settings, and disease-focused treatment centers. Headquartered in Foster City, California, Geron Corporation is positioned as a focused biotechnology company built around telomerase inhibition and commercial therapy development.
Website919 East Hillsdale Boulevard
Foster City, CA, 94404
United States
The latest articles about GERN.
Motley Fool Press Release.
Summary of Nov 17's posts. Generated by AI.
Summary of Oct 29's posts. Generated by AI.
Summary of Aug 6's posts. Generated by AI.
Summary of Oct 28's posts. Generated by AI.
Investors talking about GERN also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.